PhRMA China Office AnnouncesMr. Leo Lee, President and Managing Director of Novartis China, officially joins the PhRMA China Executive Liaison Group.
Mr. Li Yao has long been deeply involved in the biopharmaceutical industry. He has held senior management positions in multiple multinational companies, with extensive experience in strategy formulation and implementation, business development, and operational management. The PhRMA China Executive Liaison Group stated that they believe Mr. Li Yao will bring valuable experience to the PhRMA China Executive Liaison Group, while also expressing gratitude for the consistent support from member companies to PhRMA.
Novartis is one of the member companies of the Pharmaceutical Research and Manufacturers of America (PhRMA).
About PhRMA China Executive Liaison Group
The China Executive Liaison Group is composed of the General Managers of PhRMA member companies in China. As an important bridge and link between the PhRMA China office and member companies operating in China, the China Executive Liaison Group will continue to provide critical insights on China-related matters and guide the PhRMA China office in implementing its established goals and priorities, offering advice and recommendations for the development of China’s biopharmaceutical innovation ecosystem.
About Novartis
Novartis is a company focused on innovative drugs, concentrating on four core therapeutic areas: cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as five technology platforms: gene and cell therapy, radioligand therapy, xRNA therapy, chemical therapy, and biological therapy.
The Chinese name of Novartis, which means "Commitment to China," reflects the company's dedication to improving the health and quality of life of the Chinese people through continuous innovation in products and services, fully demonstrating Novartis' long-term commitment to China and its people.
Since 1987, Novartis has had over 100 innovative drugs and new indications approved in China. In 2023, Novartis' innovative drugs benefited nearly 73 million Chinese patients.